Herpes simplex virus 1 (HSV-1) replication machinery (HSV-1 replication machinery)

The Herpes simplex virus 1 (HSV-1) replication machinery is a sophisticated multi-protein system responsible for the replication of the viral genome and the assembly of new viral particles. This machinery primarily consists of the viral DNA polymerase (UL30), the processivity factor (UL42), the helicase-primase complex (UL5, UL8, and UL52), and the single-stranded DNA-binding protein (UL29) (UniProt, 2024). In oncolytic virotherapy, this machinery is genetically engineered to achieve tumor-selective replication, most commonly through the deletion of the neurovirulence gene ICP34.5, which restricts replication to cancer cells with defective antiviral defenses like impaired Protein Kinase R (PKR) signaling (PubMed, 2021). The primary therapeutic goal is to induce oncolysis, where the replication process culminates in the rupture of the cancer cell, releasing tumor-associated antigens and stimulating a robust, systemic anti-tumor immune response (NIH, 2023). While the machinery is the functional engine of therapies like Talimogene laherparepvec (T-VEC), it also serves as a safety target for antiviral drugs like acyclovir, which can inhibit the UL30 polymerase to stop viral spread in the event of adverse reactions (StatPearls, 2023).

Other names

HSV-1 DNA replication complexoHSV replication systemHerpes simplex virus 1 replisomeHSV-1 DNA polymerase complex

The machinery facilitates the synthesis of viral DNA within host cells; in oncolytic applications, it is engineered for tumor-selective replication to induce cell lysis and anti-tumor immunity, while antiviral drugs inhibit the DNA polymerase component to stop replication.